Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

European Urology

Volumn 65, Issue 3, 2014, Pages 577-584

  McKay, Rana R ^a   Kroeger, Nils ^b,c   Xie, Wanling ^d   Lee, Jae Lyun ^e   Knox, Jennifer J ^f   Bjarnason, Georg A ^g   MacKenzie, Mary J ^h   Wood, Lori ⁱ   Srinivas, Sandy ^j   Vaishampayan, Ulka N ^k   Rha, Sun Young ^l   Pal, Sumanta K ^m   Donskov, Frede ⁿ   Tantravahi, Srinivas K ^o   Rini, Brian I ^p   Heng, Daniel Y C ^b   Choueiri, Toni K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e University of Ulsan College of Medicine   (South Korea)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h LONDON REGIONAL CANCER PROGRAM   (Canada)

ⁱ QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k WAYNE STATE UNIVERSITY   (United States)

^l Yonsei University College of Medicine   (South Korea)

^m CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁿ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^o UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^p TAUSSIG CANCER INSTITUTE   (United States)

more..

Author keywords

Bone metastases; Liver metastases; mTOR inhibitors; Outcome; Renal cell carcinoma; VEGF therapy

Indexed keywords

BONE METASTASES; LIVER METASTASES; MTOR INHIBITORS; OUTCOME; RENAL CELL CARCINOMA; VEGF THERAPY;

BONE NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; RETROSPECTIVE STUDIES;

EID: 84895059211     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.08.012     Document Type: Article

References (21)

1. M. Bianchi, M. Sun, and C. Jeldres et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis Ann Oncol 23 2012 973 980
2. E. Woodward, S. Jagdev, and L. McParland et al. Skeletal complications and survival in renal cancer patients with bone metastases Bone 48 2011 160 166
3. D.Y. Heng, W. Xie, and M.M. Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
4. M.S. Pepe, K.F. Kerr, G. Longton, and Z. Wang Testing for improvement in prediction model performance Stat Med 32 2013 1467 1482
5. F. Donskov, and H. von der Maase Impact of immune parameters on long-term survival in metastatic renal cell carcinoma J Clin Oncol 24 2006 1997 2005 (Pubitemid 46622107)
6. T.M. Mekhail, R.M. Abou-Jawde, and G. Boumerhi et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma J Clin Oncol 23 2005 832 841 (Pubitemid 46224183)
7. R.J. Motzer, R.M. Bukowski, and R.A. Figlin et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 2008 1552 1558
8. S. Negrier, B. Escudier, and F. Gomez et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie Ann Oncol 13 2002 1460 1468
9. E. Segal, H. Pan, and P. Ofek et al. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics PLoS One 4 2009 e5233
10. B. Beuselinck, S. Oudard, and O. Rixe et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib Ann Oncol 22 2011 794 800
11. R.J. Motzer, B. Escudier, and S. Oudard et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
12. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 2002 584 593 (Pubitemid 37328925)
13. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342 (Pubitemid 40852708)
14. B. Beuselinck, P. Wolter, and A. Karadimou et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases Br J Cancer 107 2012 1665 1671
15. D. Keizman, M. Ish-Shalom, and R. Pili et al. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma Eur J Cancer 48 2012 1031 1037
16. G. Moriceau, B. Ory, and L. Mitrofan et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (everolimus): pivotal role of the prenylation process Cancer Res 70 2010 10329 10339
17. M. Gerlinger, A.J. Rowan, and S. Horswell et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
18. I.J. Fidler The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited Nat Rev Cancer 3 2003 453 458 (Pubitemid 37328849)
19. T.K. Choueiri, J.A. Garcia, and P. Elson et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy Cancer 110 2007 543 550 (Pubitemid 47106142)
20. R.P. Riechelmann, S. Chin, and L. Wang et al. Sorafenib for metastatic renal cancer: the Princess Margaret experience Am J Clin Oncol 31 2008 182 187 (Pubitemid 351519171)
21. S. Patil, R.A. Figlin, and T.E. Hutson et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma Ann Oncol 22 2011 295 300